Gapping up
In reaction to strong earnings/guidance: STX +2.6%, AGN +2.1%, (also Valeant Pharma delivers letter to Allergan Board; prepared to improve offer and provide value of at least $200 a share; urges Allergan Board to take control of process), HUN +2%.
M&A news: CQB +1% (Cutrale-Safra to acquire Chiquita for $14.50 per share in cash in a transaction valued at ~$1.3 billion).
Other news: ISR +32.3% (continued strength), RNA +10.8% (on negative SRPT Eteplirsen update; seen as competitive positive for RNA's DMD drug candidates), NQ +8.5% (still checking), SPEX +8.5% (light volume; continued strength), PAY +6.1% (Barron's profiles positive view; also positiive mention on MadMoney), NNVC +5% (signs CRADA for material transfer with USAMRIID for evaluating its Anti-Ebola drug candidates), AKBA +4.5% (announces positive top-line results from its Phase 2b study of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease; study meets primary endpoint), NVAX +4.3% (presents RSV F Protein Nanoparticle Vaccine Clinical Data; announces Ebola Vaccine development program), JASO +2.9% (still checking), CNIT +2.3% (Entered Strategic Partnership with Pengfeng Investment on Automobile New Media Platform), NLNK +1.4% (still checking), MU +1.1% (announces $1 bln stock buyback), TSEM +1.1% (signs definitive agreement to re-finance its bank debt with a $111 mln term loan maturing 2018), YELP +1% (reports of Tabelog interest), GILD +0.9% (favorable commentary on Friday's Mad Money), CLF +0.9% (WSJ Ahead of the Tape Column profiles positive view on Cliffs), DECK +0.7% (favorable commentary on Friday's Mad Money), NXPI +0.5% (added to IBD list), TWTR +0.3% (acquired Twitpic domain and photo archive).
Analyst comments: BABA +1.1% (initiated with a Buy at Jefferies; tgt $118), AA +0.9% (upgraded to Buy from Hold at Deutsche Bank), SHPG +0.8% (upgraded to Outperform from Mkt Perform at William Blair)